I have just noticed a new NICE guideline has been started. Only a skeleton at present - in the guideline scoping state. It will probably be years before it is completed. It is good that it has been selected for further work but must be devastating for anyone suffering TED to see how far away this (potential) treatment might be.
Teprotumumab is not licensed in the UK.
This is the public documentation for the product from the USA:
dailymed.nlm.nih.gov/dailym...
Home > NICE Guidance > Conditions and diseases > Diabetes and other endocrinal, nutritional and metabolic conditions > Thyroid disorders
Teprotumumab for treating thyroid eye disease ID 6432
Awaiting development [GID-TA11531] Expected publication date: TBC
Status Awaiting development
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6432
Project Team
Project lead scopingta@nice.org.uk
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
Date Update
10 April 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected